Meta-analysis of Zhibitai Capsules combined with statin in reducing blood lipid levels in patients with coronary heart disease.
10.19540/j.cnki.cjcmm.20200211.502
- Author:
Mei-Huan LI
1
;
Ying LI
1
;
Ming-Tai CHEN
1
;
Hai-Dan LIN
1
;
Yan-Hui WU
2
;
Zhong ZHANG
1
Author Information
1. Department of Cardiovascular Disease, Shenzhen Hospital of Traditional Chinese Medicine/Forth College of Clinical Medicine, Guangzhou University of Chinese Medicine Shenzhen 518000, China.
2. People's Hospital of Yantian District Shenzhen 518085, China.
- Publication Type:Journal Article
- Keywords:
Meta-analysis;
Zhibitai Capsules;
blood lipid level;
coronary heart disease;
statin;
systematic review
- MeSH:
Capsules;
China;
Coronary Disease;
Drugs, Chinese Herbal;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipids
- From:
China Journal of Chinese Materia Medica
2020;45(12):2966-2974
- CountryChina
- Language:Chinese
-
Abstract:
To systematically review the efficacy and safety of Zhibitai Capsules combined with chemical drugs versus chemical drugs alone in regulating blood lipid of patients of coronary heart disease, so as to provide evidence-based reference for clinical treatment. In this study, PubMed, EMbase, Cochrane Library, China Knowledge Network Database(CNKI), Technology Journal Database(VIP) and WanFang Database(WanFang) were retrieved to find the randomized controlled trials(RCT) about therapeutic efficacy of Zhibitai Capsules combined with statins(experimental group)versus statins alone(control group)in the treatment of regulating blood lipid of patients with coronary heart disease. The retrieval time was restricted to be from the inception to October 2019. The data were extracted from the randomized controlled trials. Meta-analysis was conducted by RevMan 5.3 statistical software after quality evaluation by Cochrane 5.1.0 quality evaluation tool(blood lipid level, inflammation indicators, traditional Chinese medicine syndrome score and adverse reactions). A total of 11 RCT were included, involving 1 538 patients. The results of Meta-analysis showed that in terms of decrease of total cholesterol(MD=-0.15,95%CI[-0.25,-0.05],P=0.004), decrease of triglycerides improvement(MD=-0.16,95%CI[-0.23,-0.10],P<0.000 01), decrease of low-density lipoprotein(MD=-0.08,95%CI[-0.15,-0.01],P=0.03), and increase of high-density lipoprotein(MD=0.06,95%CI[0.03,0.10],P=0.000 2), experimental group was better than control group. At the same time, the incidence of adverse reactions were low in the experimental group(OR=0.40,95%CI[0.18,0.85],P=0.02). As a result, in treatment of coronary heart disease, the therapeutic efficacy of Zhibitai Capsules combined with statins is better than statins alone in lowering total cholesterol level, triglyceride level, low-density lipoprotein level, and increasing high-density lipoprotein level. Patients in the experimental group had a low incidence of adverse events, but the heterogeneity was slightly higher, and the result had a poor stability. However, due to the small sample size of studies included, some experimental designs were not perfect, which reduces the recommendation level and evidence intensity of this system evaluation. Therefore, high-quality multi-center, large-sample, randomized, double-blind randomized controlled trials are needed for providing more reliable basis.
